pyrroles has been researched along with Cardiovascular Diseases in 403 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.25) | 18.7374 |
| 1990's | 6 (1.49) | 18.2507 |
| 2000's | 229 (56.82) | 29.6817 |
| 2010's | 155 (38.46) | 24.3611 |
| 2020's | 12 (2.98) | 2.80 |
| Authors | Studies |
|---|---|
| Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K | 1 |
| Adela, R; Durga, DR; Mounika, N; Mudimala, P | 1 |
| Dutta, D; Misra, A; Mohindra, R | 1 |
| Bhatt, DL; Buch, MH; Charles-Schoeman, C; Connell, CA; Dougados, M; Giles, JT; Koch, GG; Kwok, K; Menon, S; Rivas, JL; Szekanecz, Z; Vranic, I; Wang, C; Wu, J; Yndestad, A; Ytterberg, SR | 1 |
| Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J | 1 |
| Morinobu, A | 1 |
| Faldu, K; Krishnappa, M; Maroo, S; Mody, N; Parmar, D; Parmar, K; Patil, K; Shah, C; Trivedi, P | 1 |
| Armuzzi, A; Colombel, JF; Farnier, M; Friedman, GS; Ha, C; Kwok, K; Quirk, D; Salese, L; Sands, BE; Su, C; Taub, PR | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Kanayama, M; Miyashita, Y; Moroi, M; Nagayama, D; Ohira, M; Saiki, A; Sato, N; Shirai, K; Tatsuno, I; Watanabe, Y; Yamaguchi, T | 1 |
| Kobayashi, J | 1 |
| Blumenfeld, AM; Hutchinson, S; Lipton, RB; Lu, K; Severt, L; Silberstein, SD; Yu, SY | 1 |
| Berstein, G; Correa-da Rosa, J; Fitz, LJ; Garcet, S; Kim, J; Krueger, JG; Lee, J; Lowes, MA; Suarez-Farinas, M; Tomalin, L; Valdez, H; Wolk, R | 1 |
| Accossato, P; Choy, E; DeMasi, R; Kola, B; Lula, S; Nurmohamed, M | 1 |
| Ericsson, H; Fuhr, R; Gan, LM; Heijer, M; Kjaer, M; Lagerström-Fermér, M; Lindstedt, EL; Michaëlsson, E; Nelander, K; Whatling, C | 1 |
| Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J | 1 |
| Charles-Schoeman, C; DeMasi, R; Gladman, DD; Graham, D; Jones, T; McInnes, IB; Nurmohamed, M; Thiers, B; Veale, DJ; Wang, C; Wolk, R | 1 |
| Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H | 1 |
| Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH | 1 |
| Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
| Kennedy, RL; Malabu, UH; Vangaveti, V | 1 |
| Koh, KK | 1 |
| Boekholdt, SM; Pedersen, TR; Waters, DD | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Berberich, R; Dieplinger, B; Dieplinger, H; Ikewaki, K; Koenig, P; Kronenberg, F; Nakada, Y; Neyer, U; Salmhofer, H; Schwaiger, JP; Zitt, E | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 2 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Steurer, J | 1 |
| Medvedeva, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Alderson, P; Lewis, SR; Nicholson, A; Sanders, RD; Smith, AF | 1 |
| Ivanovic, B; Tadic, M | 1 |
| Farkouh, ME; Sethi, SS | 1 |
| Chang, CL; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Blumenthal, RS; Martin, SS; Ndumele, CE | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Groenemeijer, M; Nanayakkara, PW; Scheffer, PG; Schindhelm, RK; Simsek, S; Smulders, YM; van Verschuer, VM | 1 |
| Dabrowski, M; Wiliński, J | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Ge, J; Jang, Y; Ji, C; Kim, YJ; Lam, W; Zhu, J | 1 |
| Cohen, DJ; Cooper, CJ; Cutlip, DE; D'Agostino, RB; Dworkin, LD; Henrich, W; Jaff, MR; Jamerson, K; Lewis, EF; Massaro, JM; Matsumoto, AH; Murphy, TP; Prince, MR; Reid, DM; Rundback, JH; Shapiro, JI; Steffes, M; Tuttle, KR | 1 |
| Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y | 1 |
| Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H | 1 |
| Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C | 1 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Marques-Vidal, P; Preisig, M; Vaucher, J; Vollenweider, P; Waeber, G | 1 |
| Cho, EJ; Kim, JH; Sutradhar, S; Westergaard, M; Yunis, C | 1 |
| Aguirre, AC; Barbosa, SP; Bianco, HT; do Amaral, JB; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Hovingh, GK; Laskey, R; Vogt, L; Waters, DD | 1 |
| Lozzi, A | 1 |
| Marrett, E; Neff, DR; Ramey, DR; Tershakovec, AM; Tomassini, JE; Zhang, NJ; Zhang, Q; Zhao, C | 1 |
| Evdakimova, AA; Iakovenko, EI; Mamedov, MN; Sharvadze, GG; Toguzova, ZA | 1 |
| Breazna, A; Demetri, GD; Ewer, MS; Lenihan, DJ; Motzer, RJ; Niculescu, L; Suter, TM | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Al Zhrany, N; Atwill, M; Bennaceur, K; Breault, D; Hoffmann, J; Keavney, B; Richardson, G; Saretzki, G; Spyridopoulos, I; von Zglinicki, T | 1 |
| Doerfer, J; Grulich-Henn, J; Grünert, SC; Holder, M; Krebs, A; Lichte, K; Schmidt-Trucksäss, A; Schwab, KO; Stier, B; Winkler, K; Wöhrl, J | 1 |
| Blumenthal, RS; Greenland, P; Polonsky, TS | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW | 1 |
| Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK | 1 |
| Chatterjee, S; Majumder, A; Ray, S | 1 |
| Ye, YC; Zhang, SY; Zhao, XL | 1 |
| Stimac, D; Vojvodić, Z | 1 |
| Joshi, SR | 1 |
| Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
| Arsenault, BJ; Bao, W; Byun, YS; DeMicco, D; Laskey, R; Lee, JH; Tsimikas, S; Witztum, JL; Yang, X | 1 |
| Kritharides, L; Nicholls, SJ | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE | 1 |
| Baumgartner, I; Drechsler, C; Fauler, G; Genser, B; Grammer, TB; Krane, V; März, W; Ritz, E; Scharnagl, H; Silbernagel, G; Wanner, C | 1 |
| Baigent, C | 1 |
| Bays, H; Donahue, S; Gaudet, D; Gouni-Berthold, I; Hanotin, C; Robinson, J; Ruiz, JL; Watts, GF; Weiss, R; Zhao, J | 1 |
| Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C | 1 |
| Fenner, A | 1 |
| Adedapo, AD; Akunne, OO; Fadare, J; Godman, B; Truter, I | 1 |
| Kasiske, BL; Wheeler, DC | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ | 1 |
| Kerdel, FA | 1 |
| Benner, JS; Foody, JM; Joyce, AT; Liu, LZ; Rudolph, AE | 2 |
| Colin, X; Lafuma, A; Solesse, A | 1 |
| Todd, DJ | 1 |
| Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL | 1 |
| Martin, J | 1 |
| Vogel, RA; Willke, RJ; Zhou, S | 1 |
| Mehlsen, J | 1 |
| Benner, JS; Foody, JM; Jeffers, BW; Joyce, AT; Liu, LZ | 1 |
| Fitchett, DH; Goodman, SG; Langer, A | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Carmena, R; Chu, P; Drummond, M; Graff, J; Greten, H; Pandya, A; Shepherd, J; Taylor, DC; Thompson, D; Weinstein, MC; Wenger, N | 1 |
| Kékes, E | 1 |
| Maitland, ML | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Lenihan, DJ | 1 |
| Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC | 1 |
| Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M | 1 |
| Bittner, V; Breazna, A; DeMicco, DA; Greten, H; Grundy, SM; Johnson, C; LaRosa, JC; Waters, DD | 1 |
| Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Cziraky, M; Grochulski, D; Hoy, T; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V | 1 |
| Hoeger, KM | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 2 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Lüscher, TF | 1 |
| Holmberg, B; Stegmayr, BG | 1 |
| Schmidinger, M; Zielinski, CC | 1 |
| Porta, C; Szczylik, C | 1 |
| Koren, MJ; Kuznik, A; Mullins, CD; Rattinger, GB | 1 |
| Hirata, K; Inoue, N; Kawashima, S; Masano, T; Nakajima, K; Nishimura, K; Sasaki, N; Satomi-Kobayashi, S; Shinohara, M; Sugiyama, D; Takaya, T; Takeda, M; Tawa, H; Toh, R; Yamashita, T; Yokoyama, M | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Tokgözoğlu, L | 1 |
| Kültürsay, H | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Chu, P; Goetghebeur, M; Merikle, E; Pandya, A; Taylor, DC; Wagner, M | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA | 1 |
| Deedwania, P; Singh, V | 1 |
| Chen, HX; Cleck, JN | 1 |
| Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F | 1 |
| Davy, KP; Dengo, AL; Orr, JS; Rivero, JM | 1 |
| Castelli, P; Castiglioni, L; Consuelo Maio, R; Cosentino, M; De Leo, A; Guasti, L; Lecchini, S; Legnaro, M; Marino, F; Maroni, L; Piffaretti, G; Rasini, E; Schembri, L; Tozzi, M; Venco, A | 1 |
| Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K | 1 |
| Claudel, T; Fauler, G; März, W; Putz-Bankuti, C; Scharnagl, H; Sourij, H; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M; Wascher, TC; Winkler, K | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Ko, SK; Liew, D; Park, HJ | 1 |
| Birnbaum, H; Connolly, C; Ivanova, J; Kidolezi, Y; Kuznik, A; Signorovitch, J; Simpson, RJ | 1 |
| Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K | 1 |
| Nissen, SE | 1 |
| Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M | 1 |
| Curran, MP | 1 |
| Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW | 1 |
| Faergeman, O; Hyde, CL; Lira, M; Macinnes, A; Mazzarella, RA; Paciga, SA; Sanders, FA; Thompson, JF; van Wijk, DF; Wood, L | 1 |
| Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M | 1 |
| Kurzrock, R; Lenihan, D; Tsimberidou, AM; Vaklavas, C | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Lacchini, R; Silva, PS; Tanus-Santos, JE | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Ahn, TH; Ahn, YK; Bae, JH; Baek, SH; Choi, DJ; Choi, YJ; Hong, SJ; Hong, TJ; Hur, SH; Ihm, SH; Jang, YS; Kim, BS; Kim, DI; Kim, HS; Kim, YJ; Lee, CW; Lee, SH; Lee, SU; Park, DG; Ryu, KH; Seung, KB | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Grimm, R; Kursun, A; Malik, M; Sutradhar, S; Yunis, C | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Derosa, G; Maffioli, P | 1 |
| Brandes, AA; Franceschi, E; Girardi, F | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Geleedst-De Vooght, M; Jansen, P; Maitland-van der Zee, AH; Mantel-Teeuwisse, A; Schalekamp, T | 1 |
| Huang, QY; Liu, L; Shu, J; Xu, DY; Zhao, SP | 1 |
| Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN | 1 |
| Daida, H; Hiro, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Murohara, T; Nakagawa, Y; Ohashi, T; Ozaki, Y; Shibata, R; Yamagishi, M | 1 |
| Djamali, A; Gordon, RD; Legendre, C; Pietrangeli, CE | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Birnbaum, H; Ivanova, J; Kuznik, A; Ramakrishnan, K; Signorovitch, J; Simpson, RJ | 1 |
| Boulanger, L; Chen, SY; Mardekian, J; Rao, P; Rublee, DA; Wu, N | 1 |
| Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Wierzbicki, AS | 1 |
| Meek, CL; Pathmanathan, H; Ramsbottom, T; Reston, JD; Viljoen, A | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Buch, J; Caulfield, MJ; Collier, DJ; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS | 1 |
| Blann, AD; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Kakafika, A; Karagiannis, A; Kolovou, GD; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Petridis, D; Tziomalos, K | 1 |
| Emanueli, C; Fortunato, O; Madeddu, P; Mangialardi, G; Monopoli, A; Ongini, E; Spinetti, G | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| Jialal, I; Kaur, J | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Fujita, K; Hasuike, T; Horimatsu, T; Maruyama, T; Masuda, S; Miki, K; Nishibori, Y; Takada, M | 1 |
| Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Della-Morte, D; DeRosa, JT; Elkind, MS; Gutierrez, J; Lorenzo, D; McClendon, MS; Ratchford, EV; Rundek, T; Sacco, RL | 1 |
| Abdulhalim, AM; Grabner, M; Johnson, W; Kuznik, A; Mullins, CD | 1 |
| Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Buikema, A; Kulakodlu, M; Kuznik, A; Potash, J; Swindle, JP | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Arsenault, BJ; Barter, P; Boekholdt, SM; Chatterjee, A; Deedwania, P; DeMicco, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; LaRosa, JC; Pedersen, TR; Waters, DD | 1 |
| Saito, Y | 1 |
| Teramoto, T | 1 |
| Chan, WC; Hopkins, R; Jackson, G; Lawes, CM; Marshall, R; Thornley, S; Young, R | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Takagi, H; Umemoto, T | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Araki, A; Iimuro, S; Ito, H; Matsuyama, Y; Ohashi, Y; Sakurai, T; Shinozaki, T; Umegaki, H | 1 |
| Buhre, WF; van Klei, WA | 1 |
| Beattie, WS; Fleisher, LA | 1 |
| Bragagnolo, JC; Catalano, H; Comignani, PD; Cornejo Pucci, E; Herrera, L; Igarzabal, C; Laffaye, N; Macchia, A; Mariani, JA; Nicolucci, A; Scazziota, AS; Tognoni, G | 1 |
| Hong, T; Huo, Y; Jia, J; Jiang, J; Li, J; Liu, P; Yu, R; Zhang, Y | 1 |
| Bryson, GL; Neilipovitz, DT; Taljaard, M | 1 |
| Betteridge, J; DeMicco, DA; Fayyad, R; Holme, I; Kvien, TK; LaRosa, JC; Pedersen, TR; Semb, AG; Wun, CC | 1 |
| Scheen, AJ | 4 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Elis, A; Lishner, M | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Gogolashvili, NG | 1 |
| Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A | 1 |
| Bittner, V; DeMicco, DA; LaRosa, JC; Messig, M; Waters, DD; Wenger, NK | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Gropp, C | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M | 1 |
| Velussi, M | 1 |
| Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J | 1 |
| Ostroumova, OD | 1 |
| Coupal, L; Grover, SA; Ho, V; Lavoie, F; Pilote, L; Zowall, H | 1 |
| Athyros, VG; Boudoulas, H; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Hennekens, CH; Serebruany, VL; Steinhubl, SR | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Devroey, D; Ginst, LV | 1 |
| Ravnskov, U | 1 |
| Killestein, J | 1 |
| Trewby, P | 1 |
| Drummond, GA | 1 |
| Hackam, DG | 1 |
| De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Bernaud, C; Boutouyrie, P; Christin-Maitre, S; Gompel, A; Jaillon, P; Laurent, S; Simon, T; Thuillez, C; Zannad, F | 1 |
| Ruef, J | 1 |
| Chimienti, S; Cristofano, C; Muscogiuri, P; Vernaglione, L | 1 |
| März, W | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Fang, CH; Li, JJ | 1 |
| Hennekens, CH; Novela, C | 1 |
| Caramelli, B; De Bernoche, C; Durazzo, AE; Ikeoka, DT; Machado, FS; Monachini, MC; Puech-Leão, P | 1 |
| Economidou, O; Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K | 1 |
| Baumeister, B; Berthold, HK; Degenhardt, R; Gouni-Berthold, I; Krone, W; Unverdorben, M; Unverdorben, S; Vetter, H; Zittermann, A | 1 |
| Hamsten, A; Klareskog, L | 1 |
| Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O | 1 |
| Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R | 1 |
| Bates, ER; Carville, DG; Lau, WC | 1 |
| Hegmann, T | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 1 |
| Miller, M | 1 |
| Philips, JC; Radermecker, RP; Scheen, AJ | 1 |
| Frishman, WH; Zuckerman, AL | 1 |
| März, W; Regourd, E; Ruf, G; Vetter, S | 1 |
| von Schacky, C | 1 |
| Rollins, G | 1 |
| Bláha, V; Haas, T; Hyspler, R; Smahelová, A; Tichá, A; Zadák, Z | 1 |
| Bern, VH | 1 |
| Croom, KF; Plosker, GL | 1 |
| Baghestanian, M; Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Jacobs, PL; Johnson, BM; Nash, MS | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Pitt, B | 1 |
| Barter, P; Fruchart, JC; Gotto, AM; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Shear, C; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Eisenbarth, GS | 1 |
| Bates, ER; Lau, WC | 1 |
| McFarlane, SI; Murad, O; Palmer, J; Sowers, J | 1 |
| Cannon, CP; Ray, KK | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Cowie, MR | 1 |
| Auer, J; Eber, B; Lamm, G | 1 |
| Southern, W | 1 |
| Braunwald, E; Cannon, CP; Murphy, SA | 1 |
| Ravnskov, U; Rosch, PJ; Sutter, MC | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Smulders, YM | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K; Zisaki, K | 1 |
| Field, KM | 1 |
| Tseng, KH | 1 |
| Langmann, T; Schmitz, G | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Bays, HE; Davidson, MH; McKenney, JM; Saponaro, J; Thompson, PD | 1 |
| Biccard, BM; Foëx, P; Sear, JW | 1 |
| Langer, A | 1 |
| Robinson, JG | 1 |
| Jaber, BL; Madias, NE | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Thomason, MJ | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J | 1 |
| Cannon, CP | 1 |
| Brännström, M; Bucht, B; Crougneau, V; Dimeny, E; Ekspong, A; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Welin, D; Wikdahl, AM | 1 |
| Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH | 1 |
| Frick, B; Fuchs, D; Schroecksnadel, K; Weiss, G; Winkler, C; Wirleitner, B | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Mason, RP | 2 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Clearfield, M | 1 |
| Baheti, NN; Kulkarni, PM; Panchal, NV; Parale, GP | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Rosenson, RS | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Antoniades, C; Stefanadis, C; Tousoulis, D | 1 |
| Charlton-Menys, V; Durrington, P | 1 |
| Berneis, K; Rizzo, M | 1 |
| Fukuda, N | 1 |
| Kamyar, M; Lemmens-Gruber, R | 1 |
| d'Emden, M; Knopp, RH; Pocock, SJ; Smilde, JG | 1 |
| Plummer, CJ | 1 |
| Babapulle, MN; Brophy, JM; Costa, V; Rinfret, S | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Armani, A; Toth, PP | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Beddhu, S; Cheung, AK; Kronenberg, F; Kwan, BC | 1 |
| Kiberd, BA | 1 |
| Palacios Muñoz, R; Santos González, J | 1 |
| Barter, P; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, SM; Haffner, S; Kastelein, JJ; LaRosa, JC; Schachner, H; Shepherd, J; Waters, DD | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Hérnandez, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Cohen, JS | 1 |
| East, JE | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Tall, AR; Wang, N; Yvan-Charvet, L | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; McGuire, A; Neil, HA; Raikou, M | 1 |
| Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y | 1 |
| Graff, J; Jönsson, B; Lindgren, P; Olsson, AG; Pedersen, TJ | 1 |
| Heering, NJ | 1 |
| Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM | 1 |
| Gorbas', IM; Iakimishina, LI; Kaĭdashev, IP; Petrushov, AV; Rasin, AM; Rasin, MS; Smirnova, IP; Vasil'ev, VN | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 1 |
| Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ | 1 |
| Bittner, V; Herrington, DM; Lewis, SJ; Welty, FK; Wenger, NK | 2 |
| McClendon, KS; Riche, DM | 1 |
| Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ | 1 |
| Asher, J; Houston, M | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Pirpasopoulou, A; Skaperdas, A; Tziomalos, K | 1 |
| Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC | 1 |
| Mocanu, MM; Shakkottai, P; Yellon, DM | 1 |
| Frøbert, O; Holmager, P; Jensen, KM; Schmidt, EB; Simonsen, U | 1 |
| Benatar, JR; Stewart, RA | 1 |
| Emanuele, E; Geroldi, D | 1 |
| Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M | 1 |
| Poli, A | 1 |
| Arca, M | 1 |
| Arca, M; Gaspardone, A | 1 |
| Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Lyseng-Williamson, KA; Plosker, GL | 1 |
| Ghattas, AE; Pimenta, J | 1 |
| Hobbs, FD | 1 |
| Joensuu, H | 1 |
| Brännström, M; Bucht, S; Crougneau, V; Dimeny, E; Ekspong, A; Eriksson, M; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Stenlund, H; Wikdahl, AM | 1 |
| Bright, J | 1 |
| Levy, Y | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM | 1 |
| Amann-Vesti, B; Brockes, C; Koppensteiner, R; Kovacevic, T; Rousson, V; Simon, R; Spring, S; van der Loo, B | 1 |
| Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Mascitelli, L; Vos, E | 1 |
| Alter, RA | 1 |
| Goldstein, MR | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Clarke, LD; Johnson, SJ; Liu, LZ; Ramsey, SD; Roberts, CS; Sullivan, SD | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Gómez-Guerrero, C; Langer, A; Leiter, LA; Martín-Ventura, JL; Masramon, X | 1 |
| Doggrell, SA | 2 |
| Hariharan, S; Lowry, S | 1 |
| Cohn, LJ | 1 |
| Inman, WH; Rawson, NS | 1 |
| Atwal, KS | 1 |
| Lawson, K | 2 |
| Nielsen-Kudsk, JE | 1 |
| Farnier, M | 1 |
| Jones, PH | 1 |
| Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R | 1 |
| Angus, C; Genest, J; McPherson, R; Murray, P | 1 |
| Kluft, C | 1 |
| Quast, U | 1 |
81 review(s) available for pyrroles and Cardiovascular Diseases
| Article | Year |
|---|---|
Response to Comment on: "Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".
Topics: Cardiovascular Diseases; Humans; Phenylpropionates; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
Comment on: "Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".
Topics: Cardiovascular Diseases; Humans; Phenylpropionates; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.
Topics: Animals; Antirheumatic Agents; Biological Products; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rheumatic Diseases; Risk Factors | 2018 |
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Incidence; Lipids; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
Topics: Adult; Angioplasty; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Perioperative Care; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Sitosterols; Vascular Surgical Procedures | 2013 |
Do statins play a role in renoprotection?
Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Survival Analysis | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients.
Topics: Atorvastatin; Cardiovascular Diseases; China; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2015 |
Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Topics: Animals; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Lipids; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Risk Factors | 2015 |
[Choosing wisely when prescribing statins].
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Statins and congestive heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2008 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Relative safety profiles of high dose statin regimens.
Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin | 2008 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Design; Europe; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Interferons; Kidney Neoplasms; Palliative Care; Patient Selection; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; United States | 2009 |
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypothyroidism; Indoles; Interferons; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sunitinib; Wound Healing | 2009 |
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2009 |
[Atorvastatin in primary prevention].
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Reducing morbidity and mortality in high risk patients with statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Patient Compliance; Pyrroles; Treatment Outcome | 2010 |
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Cardiovascular Diseases; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cardiovascular System; Genetic Markers; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pyrroles; Up-Regulation | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Topics: Abatacept; Cardiovascular Diseases; Clinical Trials as Topic; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Piperidines; Pyrimidines; Pyrroles | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2012 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
Non-every day statin administration--a literature review.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency | 2012 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors | 2004 |
Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Lipid Peroxidation; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Ticlopidine | 2004 |
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Drug Utilization Review; Germany; Heptanoic Acids; Humans; Lipids; Prospective Studies; Pyrroles | 2004 |
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles | 2005 |
Statins and CVD prevention in the diabetic population: implications of the CARDS trial.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2005 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
[Statins: for the time being, do not as a rule prescribe the maximum dose].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cardiovascular Diseases; DNA-Binding Proteins; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Intestinal Mucosa; Kidney; Lipid Metabolism; Lipoproteins, HDL; Liver X Receptors; Macrophages; Niacin; Orphan Nuclear Receptors; Pyrroles; Receptors, Cytoplasmic and Nuclear | 2005 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Vasopressin antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Binding Sites; Cardiovascular Diseases; Clinical Trials as Topic; Hormone Antagonists; Humans; Indoles; Pyrroles; Pyrrolidines; Tolvaptan; Vasopressins; Water-Electrolyte Imbalance | 2006 |
What's in the CARDS?
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Statins and C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles; Risk Factors | 2007 |
The power of drug co-administration: smaller doses better outcomes.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Tetrazoles; Treatment Outcome | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Atorvastatin: pharmacological characteristics and lipid-lowering effects.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Atorvastatin: its clinical role in cerebrovascular prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke | 2007 |
The genetic determinants of atorvastatin response.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors | 2007 |
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2007 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Guidelines as Topic; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2007 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States | 2005 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Antihypertensive Agents; Benzopyrans; Cardiovascular Diseases; Cromakalim; Diazoxide; Guanidines; Guinea Pigs; Minoxidil; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Pyrans; Pyrroles; Radioligand Assay; Rats; Structure-Activity Relationship; Vasodilator Agents | 1994 |
Potassium channel activation: a potential therapeutic approach?
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Benzopyrans; Bronchodilator Agents; Calcium; Cardiovascular Diseases; Cromakalim; Hair; Humans; Intraocular Pressure; Muscle, Skeletal; Nervous System Diseases; Parasympatholytics; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Reproduction; Respiratory Tract Diseases; Synaptic Transmission; Urologic Diseases; Vasodilator Agents | 1996 |
Is there a therapeutic future for "potassium channel openers'?
Topics: Adenosine Triphosphate; Benzopyrans; Brain Diseases; Cardiovascular Diseases; Cromakalim; Humans; Ion Channel Gating; Lung Diseases; Potassium Channels; Pyrroles; Urinary Bladder Diseases | 1996 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Potassium channel openers: pharmacological and clinical aspects.
Topics: Animals; Benzopyrans; Cardiovascular Diseases; Cromakalim; Heart; Humans; Muscle, Smooth; Nervous System; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Vasodilator Agents | 1992 |
127 trial(s) available for pyrroles and Cardiovascular Diseases
| Article | Year |
|---|---|
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome | 2020 |
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Phenylpropionates; Pioglitazone; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2020 |
Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP.
Topics: Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipase; Lipoprotein Lipase; Pyrroles; Quinolines | 2022 |
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Female; Heart Disease Risk Factors; Humans; Male; Migraine Disorders; Pain; Pyridines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
Topics: Adult; Aged; Cardiovascular Diseases; Cytokines; Etanercept; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Proteomics; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Young Adult | 2018 |
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Cardiovascular Diseases; Drug Administration Schedule; Enzyme Inhibitors; Half-Life; Healthy Volunteers; Humans; Male; Middle Aged; Peroxidase; Placebos; Pyrimidines; Pyrroles; Single-Blind Method; Uric Acid; Young Adult | 2019 |
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
[Prevention of cardiovascular complications in patients undergoing aortic-iliac reconstructions by correction of inflammation and endotoxemia].
Topics: Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endotoxemia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome; Vascular Surgical Procedures | 2013 |
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Treatment Outcome | 2013 |
No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Deoxyguanosine; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Pyrroles; Simvastatin; Ubiquinone | 2013 |
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2014 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.
Topics: Acute Coronary Syndrome; Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Complications; Preoperative Care; Pyrroles; Time Factors; Ultrasonography | 2014 |
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Renal Artery; Renal Artery Obstruction; Renal Insufficiency, Chronic; Stents; Treatment Failure | 2014 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Latin America; Male; Middle Aged; Middle East; Preventive Health Services; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cell-Derived Microparticles; Cholesterol, LDL; Drug Interactions; Endothelial Progenitor Cells; Ezetimibe; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Risk | 2014 |
[Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk].
Topics: Adult; Androgens; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Erectile Dysfunction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Penile Erection; Pyrroles; Risk Factors | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin.
Topics: Adolescent; Anticholesteremic Agents; Arginine; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Homoarginine; Humans; Lipids; Male; Pilot Projects; Pyrroles; Risk Factors; Treatment Outcome | 2015 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Biomarkers; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Risk Factors | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholestanol; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2015 |
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Microcirculation; Middle Aged; Pioglitazone; Prospective Studies; Pyrroles; Radial Artery; Risk Assessment; Skin; Thiazolidinediones; Treatment Outcome; Ultrasonography | 2008 |
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides | 2009 |
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides | 2009 |
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reoperation | 2008 |
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles | 2009 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction.
Topics: Aged; Atorvastatin; Biomarkers; Biopterins; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Risk Assessment; Risk Factors; Ultrasonography; Vasodilation | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults.
Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors | 2009 |
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis | 2009 |
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
Topics: Atorvastatin; Blood Vessels; Cardiovascular Diseases; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles | 2010 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles | 2009 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tablets; Time Factors; Treatment Outcome; Triglycerides; United States | 2009 |
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Chromosomes, Human, Pair 3; Female; Gene Deletion; Gene Frequency; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR; Receptors, CCR5; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2010 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Epidemiologic Research Design; Female; Heptanoic Acids; Humans; Interleukin-6; Korea; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tablets; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2010 |
[A comparative study of the efficacy and safety Zhibitai and atorvastatin].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets | 2010 |
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Up-Regulation | 2010 |
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Therapeutic Equivalency; Treatment Outcome; Young Adult | 2010 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Pyrroles | 2011 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care | 2011 |
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-.
Topics: Aged; Aged, 80 and over; Angioplasty; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Postoperative Complications; Pyrroles; Quinolines; Retrospective Studies; Risk Factors | 2011 |
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Uric Acid | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Short-term effect of atorvastatin on carotid artery elasticity: a pilot study.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Treatment Outcome; Ultrasonography | 2011 |
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Time Factors; Treatment Outcome | 2012 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
Topics: Aged; Alleles; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2012 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Thrombin | 2012 |
Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design.
Topics: Angioplasty, Balloon, Coronary; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; China; Coronary Artery Disease; Creatine; Creatine Kinase, MB Form; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Time Factors; Treatment Outcome; Troponin I | 2012 |
STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyrroles; Risk Factors; Surgical Procedures, Operative | 2012 |
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.
Topics: Adult; Aged; Anticholesteremic Agents; Arthritis; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Risk Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Slovakia; Treatment Outcome | 2013 |
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2002 |
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Cardiovascular Diseases; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Time; United States | 2003 |
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor | 2003 |
Rationale, design and methods of the CASHMERE study.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Endpoint Determination; Estrogen Replacement Therapy; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Prospective Studies; Pyrroles; Research Design; Treatment Outcome | 2004 |
Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?
Topics: Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Patient Compliance; Postoperative Complications; Prospective Studies; Pyrroles; Risk Factors; Time Factors; Vascular Surgical Procedures | 2004 |
Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Triglycerides | 2004 |
Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women.
Topics: Aged; Aging; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cardiovascular Diseases; Collagen; Collagen Type I; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Osteocalcin; Peptides; Postmenopause; Prospective Studies; Pyrroles; Risk Factors | 2004 |
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor | 2004 |
Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Skin | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides | 2005 |
Statin treatment of patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors | 2005 |
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Proportional Hazards Models; Pyrroles; Risk Factors; Time Factors; Treatment Outcome | 2005 |
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin | 2005 |
Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Triglycerides | 2005 |
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Effects of atorvastatin on higher functions.
Topics: Atorvastatin; Cardiovascular Diseases; Cognition; Female; Heptanoic Acids; Humans; Intelligence Tests; Male; Mental Processes; Middle Aged; Pyrroles; Treatment Outcome | 2006 |
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents | 2006 |
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome | 2006 |
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2006 |
High-dose atorvastatin after stroke or transient ischemic attack.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
The CARDS trial: diabetic patients dealt a winning hand.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors | 2006 |
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2007 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Effect of torcetrapib on the progression of coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional | 2007 |
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2007 |
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2007 |
Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk.
Topics: Administration, Inhalation; Adult; Atorvastatin; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperoxia; Hypoxia; Lipoproteins; Male; Middle Aged; Nitroglycerin; Oxygen; Pyrroles; Regional Blood Flow; Research Design; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasoconstriction; Vasodilation; Vasodilator Agents | 2008 |
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk | 2007 |
Effects of torcetrapib in patients at high risk for coronary events.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines | 2007 |
Efficacy of atorvastatin when not administered daily.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles; Sex Factors; Survival Analysis; Treatment Outcome; United States | 2008 |
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Prospective Studies; Pyrroles | 2005 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Topics: Aged; Ankle; Atorvastatin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Arteries; Disease Progression; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Prospective Studies; Pyrroles; Research Design; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Topics: Adiponectin; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides | 2008 |
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyridines; Pyrroles; Safety | 2001 |
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholest
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Canada; Cardiovascular Diseases; Cholesterol, LDL; Female; Health Education; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Factors; Women's Health | 2001 |
196 other study(ies) available for pyrroles and Cardiovascular Diseases
| Article | Year |
|---|---|
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Secondary Prevention | 2023 |
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Incidence; Pyrroles; Risk Factors; Treatment Outcome | 2023 |
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Heart Disease Risk Factors; Humans; Inflammation; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease.
Topics: Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Pyrroles; Quinolines | 2022 |
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2019 |
Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Heptanoic Acids; Hypoxia; Oxidative Stress; Pyrroles; Rats; Treatment Outcome | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Statin treatment and diabetes.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
How to balance cardiometabolic benefits and risks of statins.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Reply: To PMID 23219296.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Renal Dialysis | 2013 |
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Fatty Liver; Heptanoic Acids; Humans; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Patient Compliance; Pyrroles; Risk; Risk Reduction Behavior | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
[Statins after drug discontinuation are usually well tolerated].
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Retreatment; Retrospective Studies; Simvastatin | 2013 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Drug Synergism; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Pyrroles; Risk Factors | 2013 |
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
ASK NOT what CRP can do for you.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Pyrroles | 2013 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation | 2014 |
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins for millions more?
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Participation; Practice Guidelines as Topic; Primary Prevention; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; United Kingdom | 2014 |
Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease.
Topics: Aged; American Heart Association; Atorvastatin; Cardiovascular Diseases; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Societies, Medical; United States | 2014 |
Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States | 2014 |
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Hypertension; Incidence; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Middle Aged; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cholesterol, LDL; Dose-Response Relationship, Drug; Enzyme Induction; Genes, Reporter; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Risk; Telomerase; Telomere; Telomere Homeostasis | 2014 |
Coronary artery calcium score.
Topics: Atorvastatin; Calcium; Cardiovascular Diseases; Coronary Vessels; Diet; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Middle Aged; Pyrroles; Risk; Tomography, X-Ray Computed; Vascular Calcification | 2014 |
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases | 2014 |
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2015 |
Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Treatment Outcome; Triglycerides | 2015 |
Trends in statin consumption and cardiovascular mortality in Croatia 2004-2012.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Child; Child, Preschool; Croatia; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Young Adult | 2014 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road?
Topics: Apolipoprotein B-100; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Phospholipids; Pyrroles | 2015 |
Cholesterol metabolism and statin effectiveness in hemodialysis patients.
Topics: Cardiovascular Diseases; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Male; Pyrroles | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States | 2016 |
Kidney cancer: TKIs associated with stroke risk.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles | 2015 |
Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future.
Topics: Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nigeria; Practice Patterns, Physicians'; Prospective Studies; Pyrroles; Risk Factors | 2016 |
Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.
Topics: Cardiovascular Diseases; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis | 2016 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2016 |
Update on TNF Inhibitors.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cardiovascular Diseases; Certolizumab Pegol; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Etanercept; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Drug Utilization Review; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Survival Analysis; United States | 2008 |
Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetic Angiopathies; France; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles | 2008 |
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pyrroles; Treatment Outcome; Uric Acid | 2008 |
Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Insurance Claim Review; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Health Maintenance Organizations; Heptanoic Acids; Humans; Preferred Provider Organizations; Pyrroles; Simvastatin; Treatment Outcome; United States | 2008 |
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2008 |
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Europe; Heptanoic Acids; Humans; Markov Chains; Pyrroles; Quality-Adjusted Life Years | 2009 |
Cardiovascular toxicity of new agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cardiovascular Diseases; Cardiovascular System; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk; Simvastatin; United States | 2008 |
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study.
Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis | 2009 |
Polycystic ovary syndrome, inflammation, and statins: do we have the right target?
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Testosterone | 2009 |
The TNT study, women and cancer.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
Statin therapy as the fundamental therapy for cardiovascular prevention: be careful.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain.
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Regression Analysis; Renal Dialysis; Weight Gain | 2009 |
Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Models, Economic; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Topics: Aged; Atorvastatin; Canada; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis | 2009 |
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult | 2009 |
Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endarterectomy; Female; Femoral Artery; Gene Expression; Heptanoic Acids; Humans; Interleukin-8; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Peripheral Vascular Diseases; Pyrroles; Receptor, Angiotensin, Type 1; Triglycerides | 2009 |
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Korea; Male; Markov Chains; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2009 |
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Benefit Plans, Employee; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2009 |
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Time Factors | 2010 |
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Topics: Absenteeism; Adult; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Employment; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Simvastatin | 2011 |
Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Time Factors; Treatment Outcome | 2012 |
Statin wars: efficacy vs. cost.
Topics: Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2011 |
Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care.
Topics: Adult; Aged; Atorvastatin; Body Mass Index; Cardiovascular Diseases; England; Family Practice; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin | 2011 |
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes.
Topics: Adult; Aged; Angiogenic Proteins; Asian People; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Diabetes Mellitus; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Pyrroles; von Willebrand Factor; White People | 2011 |
Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells.
Topics: Aged; Anticholesteremic Agents; Apoptosis; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leukocytes, Mononuclear; Male; Middle Aged; Neovascularization, Physiologic; Nitrates; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Ornithine; Proto-Oncogene Proteins c-akt; Pyrroles; Stem Cells | 2011 |
The cholesterol ester transfer protein inhibitor, anacetrapib.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Oxazolidinones; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
The value of atorvastatin over the product life cycle in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Utilization Review; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Simvastatin; Time Factors; United States | 2011 |
Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Multivariate Analysis; Pyrroles; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; United States | 2011 |
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-pres
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Proportional Hazards Models; Pyrroles | 2012 |
Anti-inflammatory effects of perioperative statin therapy.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
Perioperative statin therapy: understanding the evidence in a Bayesian context.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides | 2012 |
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin | 2013 |
A piece of my mind: A pain in the tuches.
Topics: Anticholesteremic Agents; Atorvastatin; Buttocks; Cardiovascular Diseases; Heptanoic Acids; Humans; Medication Adherence; Mortality, Premature; Muscular Diseases; Pain; Physicians; Pyrroles; Sciatica; Self Care | 2012 |
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2002 |
[Absolutely essential in cardiovascular high risk patients. Statins--more than only anticholesteremic drugs].
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk; Survival Rate | 2002 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines | 2002 |
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Cost of Illness; Cost-Benefit Analysis; Direct Service Costs; Efficiency; Female; Health Care Costs; Health Expenditures; Heptanoic Acids; Humans; Hypolipidemic Agents; Life Expectancy; Male; Middle Aged; Primary Prevention; Pyrroles; Sensitivity and Specificity | 2003 |
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Research; Ticlopidine | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Sex Factors | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hypertension; Pyrroles; Research Design | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Risk | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black People; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Risk Factors | 2003 |
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom | 2003 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Statins in rheumatoid arthritis--two birds with one stone?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2004 |
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone | 2004 |
Clinical significance of the atorvastatin-clopidogrel drug-drug interaction.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Sample Size; Ticlopidine | 2004 |
Battle of the statins, or how the news media can change patient care.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms | 2004 |
[Statin therapy in patients with acute coronary syndrome. "Prove-it" study].
Topics: Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2004 |
Study suggests statins for diabetics with healthy LDL cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2004 |
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Sterols | 2005 |
[CARDS confirms usefulness of LDL lowering in type 2 diabetics].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Time Factors | 2004 |
Combined hyperlipidemia in a single subject with tetraplegia: ineffective risk reduction after atorvastatin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cervical Vertebrae; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Male; Odds Ratio; Pyrroles; Spinal Cord Injuries; Treatment Failure; Triglycerides; Wounds, Gunshot | 2004 |
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk | 2005 |
Controversies in antiplatelet therapy for patients with cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pyrroles | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Simvastatin | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Rhabdomyolysis | 2005 |
Ready, aim, treat to hit new cholesterol targets.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Reference Values | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Triglycerides | 2005 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
[Considerable LDL lowering is advantageous].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Placebos; Pyrroles; Risk; Risk Factors; Triglycerides | 2005 |
Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Acids; Female; Heptanoic Acids; Humans; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Risk; Treatment Outcome | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
The pharmaco-economics of peri-operative statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Monitoring; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Perioperative Care; Prospective Studies; Pyrroles; State Medicine; United Kingdom; Vascular Surgical Procedures | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke | 2005 |
The IDEAL cholesterol: lower is better.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2005 |
Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells.
Topics: Anti-Inflammatory Agents; Atorvastatin; Cardiovascular Diseases; Concanavalin A; Dose-Response Relationship, Drug; Heptanoic Acids; Homocystine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Neopterin; Oxidative Stress; Phytohemagglutinins; Pyrroles | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
A rationale for combination therapy in risk factor management: a mechanistic perspective.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Disease Management; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Humans; Nitric Oxide; Pyrroles; Risk Factors | 2005 |
Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
Topics: Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk; Triglycerides | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Statins and antioxidant vitamins: should co-administration be avoided?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Calcinosis; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Vitamin E | 2006 |
Development of gene therapies for cardiovascular and renal diseases by nucleic acid medicines.
Topics: Amides; Animals; Base Sequence; Cardiovascular Diseases; DNA, Antisense; Gene Silencing; Genetic Therapy; Hypertension, Renovascular; Imidazoles; Kidney Diseases; Male; Oligonucleotides, Antisense; Platelet-Derived Growth Factor; Promoter Regions, Genetic; Pyrroles; Rats; RNA, Catalytic; Swine; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tunica Intima | 2006 |
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Pyrroles; Quebec; Retrospective Studies; Stents; Ticlopidine | 2006 |
Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis | 2006 |
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2006 |
[HIV infection: from Pneumocystis to statins].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors | 2006 |
Does the metabolic syndrome help to select patients requiring high statin dose?
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Incidence; Metabolic Syndrome; Patient Selection; Pyrroles; Risk Assessment; Risk Factors | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis | 2006 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
The failure of torcetrapib: was it the molecule or the mechanism?
Topics: Angina Pectoris; Animals; Anticholesteremic Agents; Atorvastatin; Cardiac Output, Low; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Mice; Myocardial Revascularization; Pyrroles; Quinolines; Rabbits; Treatment Failure | 2007 |
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Models, Economic; Primary Prevention; Pyrroles; Quality-Adjusted Life Years | 2007 |
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quality of Life; Simvastatin; Survival Rate; Time Factors | 2007 |
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke | 2007 |
[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Body Weight; Cardiovascular Diseases; Heptanoic Acids; Humans; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Rural Health; Rural Population; Ukraine | 2006 |
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States | 2007 |
Atorvastatin + amlodipine: new drug. Just a commercial ploy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; France; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome; Vasodilator Agents | 2007 |
Summaries for patients. High- or low-dose atorvastatin in elderly patients with stable coronary artery disease.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regression Analysis; Risk Factors; Triglycerides | 2007 |
A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins".
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Cardiac toxicity of sunitinib.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2007 |
American Heart Association--Scientific Sessions 2007. Part 1.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Drugs, Investigational; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Molecular Structure; Pyrroles | 2008 |
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Quinolines; Treatment Outcome | 2008 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Mortality; Pyrroles | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Research Design | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles | 2008 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |
Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Primary Prevention; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years | 2008 |
The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Pyrroles; Quinolines; Research Design | 2008 |
Cardiotoxicity associated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2008 |
Torcetrapib and coronary events.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure | 2008 |
Zomepirac and cardiovascular deaths.
Topics: Analgesics; Cardiovascular Diseases; Humans; Pyrroles; Tolmetin | 1983 |
Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Topics: Animals; Arteries; Asthma; Benzopyrans; Bronchi; Cardiovascular Diseases; Cromakalim; Female; Guinea Pigs; Humans; Male; Membrane Potentials; Muscle Contraction; Muscle, Smooth; Muscle, Smooth, Vascular; Potassium Channels; Pyrroles; Sulfonylurea Compounds; Synaptic Transmission; Trachea; Vasodilator Agents | 1996 |
The nature of the statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2000 |
Is C-reactive protein an additional, surrogate end-point for statin treatment?
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Sensitivity and Specificity; Triglycerides | 2002 |